Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224598 · ClinicalTrials.gov registry record · Phase 2
A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
A Phase 2 study of Dermatosis Papulosa Nigra, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT03224598 is a Phase 2 study of Dermatosis Papulosa Nigra that has completed, run by Aclaris Therapeutics. The registered enrollment target is 39 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03224598, a Phase 2 study of Dermatosis Papulosa Nigra, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.
Conditions Studied
Interventions
- DRUG A-101 Topical Solution 40%
Study Locations (2)
District of Columbia
- Aclaris Investigational Site - Washington D.C.
New York
- Aclaris Investigational Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-06-26 |
| Est. Completion | 2019-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03224598
The ClinicalTrials.gov registry entry for NCT03224598 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatosis Papulosa Nigra appearing as the primary indexed condition, and to 1 intervention - of which A-101 Topical Solution 40% is the first listed.
NCT03224598 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, New York.
Frequently Asked Questions
What is clinical trial NCT03224598 about?
NCT03224598 is a clinical study titled "A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra". Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.
What is the current status of trial NCT03224598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2017-06-26. Estimated completion is 2019-01-08.
What conditions does trial NCT03224598 study?
This clinical trial studies the following conditions: Dermatosis Papulosa Nigra.
What interventions are being tested in trial NCT03224598?
The interventions under investigation include: A-101 Topical Solution 40% (DRUG).
Who is sponsoring clinical trial NCT03224598?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03224598 being conducted?
This trial has 2 study locations across District of Columbia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatosis Papulosa Nigra
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.